This company seems to have been delisted
Reason: Rebranded as Talphera
Last recorded trade on: March 13, 2024
Source: https://www.fiercepharma.com/marketing/acelrx-becomes-talphera-adopting-new-name-reflect-pain-pivot
Reason: Rebranded as Talphera
Last recorded trade on: March 13, 2024
Source: https://www.fiercepharma.com/marketing/acelrx-becomes-talphera-adopting-new-name-reflect-pain-pivot
AcelRx Pharmaceuticals
ACRX
$1.15
Share price
7.50%
Change (1 day)
39.89%
Change (1 year)
Categories
Revenue for AcelRx Pharmaceuticals (ACRX)
Revenue in 2023 (TTM): S$0.87 Million
According to AcelRx Pharmaceuticals
's latest financial reports the company's current revenue (TTM 
) is S$0.87 Million. In 2022 the company made a revenue of S$0.33 Million a decrease over the revenue in the year 2021 that were of S$3.8 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for AcelRx Pharmaceuticals from 2010 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | S$0.87 M | 158.73% |
| 2022 | S$0.33 M | -91.13% |
| 2021 | S$3.8 M | -46.83% |
| 2020 | S$7.16 M | 132.18% |
| 2019 | S$3.08 M | 5.02% |
| 2018 | S$2.93 M | -72.52% |
| 2017 | S$10.69 M | -57.43% |
| 2016 | S$25.12 M | -7.81% |
| 2015 | S$27.24 M | 295.28% |
| 2014 | S$6.89 M | -81.56% |
| 2013 | S$37.37 M | 1176.75% |
| 2012 | S$2.92 M | 110.88% |
| 2011 | S$1.38 M | |
| 2010 | N/A |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 | S$9.54 M | 996.31% | 🇺🇸 USA |
 | S$0.10 B | 11,476.04% | 🇺🇸 USA |